We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Clotting Initiator Blamed for Hepatitis Liver Damage

By Biotechdaily staff writers
Posted on 14 Jul 2003
Researchers have identified a protein that triggers the formation of blood clots in the minute blood vessels of the liver in patients with chronic viral hepatitis and may be the cause of the damage caused to the liver during the infection.

Investigators at the University of Toronto (Canada) genetically engineered a line of mice lacking the gene for production of fg12/fibroleukin prothrombinase. More...
When infected with a mouse hepatitis (corona) virus, these mice failed to generate blood clotting and 40% of the mice were still alive 14 days after being infected. Normal mice infected with the virus experienced blood clotting and died within four to seven days of hepatitis infection.

In addition to the tests on mice, liver biopsies from 23 human patients with severe chronic hepatitis B and 13 patients with minimal chronic hepatitis were examined to determine their fg12/fibroleukin prothombinase concentrations and the severity of clotting in their liver tissue. The results, published in the July 1, 2003, issue of the Journal of Clinical Investigation, showed that patients with severe chronic hepatitis expressed fgl2 protein in their livers in association with fibrin clots resulting in liver cell death. Patients with mild chronic hepatitis B had no evidence of fgl2 expression or clotting within their livers.

"This offers new hope to patients by paving the way for future therapies that will change the course of hepatitis,” said senior author Dr. Philip Marsden, professor of medicine at the University of Toronto. "Our work represents an innovative new approach to combating viral disease. Therapies to date have focused on getting rid of the virus, but this work points the way to blocking the damage the virus does.”




Related Links:
University of Toronto

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.